From fibrosis and cancer to obesity, Alzheimer's and aging: New paper reveals broad potential of TNIK as a therapeutic target.

A new paper published in Trends in Pharmacological Sciences by researchers at Insilico Medicine and ETH Zurich highlights the potential of TNIK as a therapeutic target for various aging-related diseases, including fibrosis, cancer, obesity, and Alzheimer's. The lead drug in Insilico's pipeline, INS018_055, is an AI-designed TNIK inhibitor currently in Phase II trials for idiopathic pulmonary fibrosis. TNIK has been found to play a significant role in cell migration, cytoskeletal organization, and cell proliferation in both healthy and malignant cells. The paper also explores TNIK's potential as a metabolic controller for combating obesity and Type 2 diabetes, as well as its emerging role in neurodegeneration. The researchers attribute TNIK's involvement in multiple diseases to its association with major hallmarks of aging. [Extracted from the article]